Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial

Background: By the early 1980s, tuberculosis treatment was shortened from 24 to 6 months, maintaining relapse rates of 1-2%. Subsequent trials attempting shorter durations have failed, with 4-month arms consistently having relapse rates of 15-20%. One trial shortened treatment only among those witho...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ray Y., Via, Laura E., Dodd, Lori E., Walzl, Gerhard, Malherbe, Stephanus T., Loxton, André G., Dawson, Rodney, Wilkinson, Robert J., Thienemann, Friedrich, Tameris, Michele, Hatherill, Mark, Diacon, Andreas H., Liu, Xin, Xing, Jin, Jin, Xiaowei, Ma, Zhenya, Pan, Shouguo, Zhang, Guolong, Gao, Qian, Jiang, Qi, Zhu, Hong, Liang, Lili, Duan, Hongfei, Song, Taeksun, Alland, David, Tartakovsky, Michael, Rosenthal, Alex, Whalen, Christopher, Duvenhage, Michael, Cai, Ying, Goldfeder, Lisa C., Arora, Kriti, Smith, Bronwyn, Winter, Jill, Barry III, Clifton E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841574/
https://www.ncbi.nlm.nih.gov/pubmed/29528048
http://dx.doi.org/10.12688/gatesopenres.12750.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841574/
https://www.ncbi.nlm.nih.gov/pubmed/29528048
http://dx.doi.org/10.12688/gatesopenres.12750.1

Ejemplares similares